These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463 [No Abstract] [Full Text] [Related]
3. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. Baudy AR; Dogan T; Flores-Mercado JE; Hoeflich KP; Su F; van Bruggen N; Williams SP EJNMMI Res; 2012 May; 2(1):22. PubMed ID: 22651703 [TBL] [Abstract][Full Text] [Related]
4. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651 [TBL] [Abstract][Full Text] [Related]
5. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. Kopetz S; Desai J; Chan E; Hecht JR; O'Dwyer PJ; Maru D; Morris V; Janku F; Dasari A; Chung W; Issa JP; Gibbs P; James B; Powis G; Nolop KB; Bhattacharya S; Saltz L J Clin Oncol; 2015 Dec; 33(34):4032-8. PubMed ID: 26460303 [TBL] [Abstract][Full Text] [Related]
6. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib. Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688 [TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495 [TBL] [Abstract][Full Text] [Related]
8. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972 [TBL] [Abstract][Full Text] [Related]
9. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma. Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164 [TBL] [Abstract][Full Text] [Related]
11. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658 [TBL] [Abstract][Full Text] [Related]
12. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853 [TBL] [Abstract][Full Text] [Related]
17. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539 [TBL] [Abstract][Full Text] [Related]
18. Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy. Yu H; Ma M; Yan J; Xu L; Yu J; Dai J; Xu T; Tang H; Wu X; Li S; Lian B; Mao L; Chi Z; Cui C; Guo J; Kong Y J Transl Med; 2017 Dec; 15(1):243. PubMed ID: 29202777 [TBL] [Abstract][Full Text] [Related]
19. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896 [TBL] [Abstract][Full Text] [Related]
20. Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. Kawaguchi K; Igarashi K; Murakami T; Zhao M; Zhang Y; Chmielowski B; Kiyuna T; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM J Cell Biochem; 2017 Aug; 118(8):2314-2319. PubMed ID: 28106277 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]